MiniPDX-guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular c
- PDF / 1,764,535 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 77 Downloads / 157 Views
ORIGINAL ARTICLE
MiniPDX‑guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma Long Yang1,2 · Zheyue Yuan2 · Yamin Zhang2 · Zilin Cui2 · Yang Li2 · Jiancun Hou2 · Xiaolong Liu2 · Zirong Liu2 · Rui Shi2 · Qing Tian2 · Jian Wang2 · Lianjiang Wang2 Received: 6 June 2020 / Accepted: 14 October 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Background The recurrence rate of hepatocellular carcinoma (HCC) after partial hepatectomy is still high. How to choose the most appropriate anti-tumor drug in the early postoperative period is crucial to improve the prognosis of patients. Recently, MiniPDX has been widely used as a new and reliable preclinical research model capable of predicting the sensitivities of anti-tumor drugs. Methods Twenty-eight patients with HCC were selected to use the MiniPDX model to screen the most sensitive anti-tumor drugs from five groups of drug regimens for preventive treatment after partial hepatectomy, and another 42 patients with HCC were selected to be treated with Sorafenib during the same period as the control group. The tumor-free survival rate and overall survival rate were analyzed and compared between these two groups. The relationship between drug sensitivity and biomarkers related to HCC was also analyzed. Results Kaplan–Meier survival curve analysis showed that the tumor-free survival (DFS) of patients in the MiniPDX group was significantly longer than that in the control group (median DFS: 25.8 months vs. 18.2 months, P = 0.022, HR 2.19, 95% CI 1.17–4.12). The overall survival (OS) of the patients in the MiniPDX group was also longer than that in the control group (median OS: 29.4 months vs. 23.8 months, P = 0.039, HR 2.37, 95% CI 1.12–5.00). The longest follow-up period was 36 months. The relationship analyzed between the efficacy of the five drugs (Regorafenib, Regorafenib, Lenvatinib, Gemcitabine, 5-FU + Oxaliplatin) and AFP, Ki-67, VEGFR, FGFR, P53, and Nrf2 showed different correlations. Conclusion The use of the MiniPDX model to select drugs to guide anti-tumor treatment after partial hepatectomy could effectively prolong the survival of patients with HCC. Keywords Hepatocellular carcinoma · MiniPDX · Targeted drugs · Chemotherapy · Survival
Introduction Primary liver cancer is one of the most common malignant tumors, ranking sixth in the incidence of malignant tumors worldwide and second in the cause of tumor death [1]. Approximately 90% cases of primary liver cancer cases are hepatocellular carcinoma (HCC), and liver resection is currently the preferred treatment. However, because of the * Yamin Zhang [email protected] 1
Medical School of Nankai University, No. 94, Weijin Road, Nankai District, Tianjin, China
Department of Hepatobiliary Surgery, Tianjin First Central Hospital, School of Medicine, Nankai University, No. 24 Fukang Road, Nankai District, Tianjin, China
2
high malignancy of HCC, the recurrence rate is still high after radical resection. According
Data Loading...
